title: Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men.
abstract: BACKGROUND
  Symptoms of fluid retention in GH-deficient patients during GH replacement are greater in men than in women, suggesting that testosterone may augment or estradiol may attenuate the antinatriuretic actions of GH. The mechanisms underlying the sodium-retaining effects of GH are poorly understood.
  
  
  OBJECTIVE
  The aim of this study was to investigate the effects of GH and testosterone, alone and in combination, on extracellular water (ECW) and the hormonal mechanisms involved.
  
  
  METHODS
  Two separate, open-label, randomized, two-period, crossover studies were performed; the first compared the effects of GH alone with those of GH and testosterone, and the second compared the effects of testosterone alone with those of GH and testosterone.
  
  
  METHODS
  Twelve hypopituitary men with GH deficiency and hypogonadism were studied.
  
  
  METHODS
  During the weeks of intervention, GH (0.5 mg/d) and testosterone enanthate (250 mg) were administered by im injection.
  
  
  METHODS
  The outcome measures were ECW, IGF-I, plasma renin activity (PRA), aldosterone (Aldo), and atrial natriuretic peptide (ANP).
  
  
  RESULTS
  GH treatment significantly increased (P < 0.05) both IGF-I and ECW, and these changes were enhanced by cotreatment with testosterone (P = 0.07 for both). PRA, Aldo, and ANP levels did not change. Testosterone treatment alone did not change the IGF-I concentration, whereas cotreatment with GH induced a marked increase. Testosterone alone increased (P < 0.05) ECW, and the effect was augmented (P < 0.01) by cotreatment with GH. Although PRA and ANP did not change, plasma Aldo decreased after single and combined treatments.
  
  
  CONCLUSIONS
  GH and testosterone exerted independent and additive effects on ECW. The mechanisms of fluid retention for both hormones are likely to be exerted on the renal tubules. This is the first direct evidence that testosterone increases ECW.
authors.affiliation: Pituitary Research Unit, Garvan Institute of Medical Research, St. Vincent's Hospital, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia.
authors.forename: Gudmundur
authors.initials: G
authors.lastname: Johannsson
authors.forename: James
authors.initials: J
authors.lastname: Gibney
authors.forename: Troels
authors.initials: T
authors.lastname: Wolthers
authors.forename: Kin-Chuen
authors.initials: KC
authors.lastname: Leung
authors.forename: Ken K Y
authors.initials: KK
authors.lastname: Ho
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001834:Body Water / Q000378:metabolism*; D018592:Cross-Over Studies; D004357:Drug Synergism; D045604:Extracellular Fluid / Q000378:metabolism*; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D019382:Human Growth Hormone; D013739:Testosterone; D000450:Aldosterone; D007334:Insulin-Like Growth Factor I; D009320:Atrial Natriuretic Factor